Status:
COMPLETED
A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers
Lead Sponsor:
Merrimack Pharmaceuticals
Collaborating Sponsors:
Sanofi
Conditions:
Epithelial Ovarian Cancer
Fallopian Tube Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
To determine whether the combination of MM-121 plus paclitaxel is more effective than paclitaxel alone
Detailed Description
This is a multicenter, open-label, randomized, Phase II study of MM-121 in patients with platinum resistant or refractory recurrent/advanced ovarian cancers. Up to 210 patients will be randomized (2:1...
Eligibility Criteria
Inclusion
- Locally advanced/metastatic or recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer
- Received at least one prior platinum based chemotherapy regimen
- Platinum-resistant or refractory
- Eligible for weekly paclitaxel
- Adequate liver and kidney function
- 18 years of age or above
Exclusion
- Evidence of any other active malignancy
- History of severe allergic reactions to paclitaxel or other drugs formulated in Cremophor®EL
Key Trial Info
Start Date :
October 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2015
Estimated Enrollment :
223 Patients enrolled
Trial Details
Trial ID
NCT01447706
Start Date
October 1 2011
End Date
June 1 2015
Last Update
May 12 2016
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Arizona Center for Cancer Care
Glendale, Arizona, United States, 85306
2
Pinnacle Oncology
Scottsdale, Arizona, United States, 85258
3
Comprehensive Blood and Cancer Center
Bakersfield, California, United States, 93309
4
Wilshire Oncology Medical Group
Corona, California, United States, 92879